129 related articles for article (PubMed ID: 10436775)
1. Pathology of incipient pancreatic cancer.
Hruban RH; Wilentz RE; Goggins M; Offerhaus GJ; Yeo CJ; Kern SE
Ann Oncol; 1999; 10 Suppl 4():9-11. PubMed ID: 10436775
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression.
Wilentz RE; Geradts J; Maynard R; Offerhaus GJ; Kang M; Goggins M; Yeo CJ; Kern SE; Hruban RH
Cancer Res; 1998 Oct; 58(20):4740-4. PubMed ID: 9788631
[TBL] [Abstract][Full Text] [Related]
3. [Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma].
Tomaszewska R
Folia Med Cracov; 1999; 40(1-2):101-41. PubMed ID: 10909469
[TBL] [Abstract][Full Text] [Related]
4. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
5. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.
Goggins M; Hruban RH; Kern SE
Am J Pathol; 2000 May; 156(5):1767-71. PubMed ID: 10793087
[TBL] [Abstract][Full Text] [Related]
6. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas.
Wada K
J Hepatobiliary Pancreat Surg; 2002; 9(1):76-85. PubMed ID: 12021900
[TBL] [Abstract][Full Text] [Related]
7. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
Wilentz RE; Iacobuzio-Donahue CA; Argani P; McCarthy DM; Parsons JL; Yeo CJ; Kern SE; Hruban RH
Cancer Res; 2000 Apr; 60(7):2002-6. PubMed ID: 10766191
[TBL] [Abstract][Full Text] [Related]
8. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas.
Brat DJ; Lillemoe KD; Yeo CJ; Warfield PB; Hruban RH
Am J Surg Pathol; 1998 Feb; 22(2):163-9. PubMed ID: 9500216
[TBL] [Abstract][Full Text] [Related]
9. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.
Moskaluk CA; Hruban RH; Kern SE
Cancer Res; 1997 Jun; 57(11):2140-3. PubMed ID: 9187111
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
Zhang L; Sanderson SO; Lloyd RV; Smyrk TC
Am J Surg Pathol; 2007 Aug; 31(8):1191-5. PubMed ID: 17667542
[TBL] [Abstract][Full Text] [Related]
11. Precursor lesions of pancreatic cancer: molecular pathology and clinical implications.
Singh M; Maitra A
Pancreatology; 2007; 7(1):9-19. PubMed ID: 17449961
[TBL] [Abstract][Full Text] [Related]
12. [Genetics of pancreatic cancer: recent advances in molecular diagnosis].
Hayashi N; Egami H; Ogawa M
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):476-81. PubMed ID: 12094699
[TBL] [Abstract][Full Text] [Related]
13. Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study.
Agoff SN; Crispin DA; Bronner MP; Dail DH; Hawes SE; Haggitt RC
Mod Pathol; 2001 Mar; 14(3):139-46. PubMed ID: 11266517
[TBL] [Abstract][Full Text] [Related]
14. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers.
Laghi L; Orbetegli O; Bianchi P; Zerbi A; Di Carlo V; Boland CR; Malesci A
Oncogene; 2002 Jun; 21(27):4301-6. PubMed ID: 12082617
[TBL] [Abstract][Full Text] [Related]
15. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins M; Schutte M; Lu J; Moskaluk CA; Weinstein CL; Petersen GM; Yeo CJ; Jackson CE; Lynch HT; Hruban RH; Kern SE
Cancer Res; 1996 Dec; 56(23):5360-4. PubMed ID: 8968085
[TBL] [Abstract][Full Text] [Related]
16. [Differential genetic pathway of duct and acinar carcinomas of the pancreas].
Tsutsumi M
Gan To Kagaku Ryoho; 2005 May; 32(5):593-8. PubMed ID: 15918556
[TBL] [Abstract][Full Text] [Related]
17. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas.
Mueller J; Gansauge S; Mattfeldt T
Hepatogastroenterology; 2003; 50(50):541-4. PubMed ID: 12749268
[TBL] [Abstract][Full Text] [Related]
18. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
Caldas C; Hahn SA; Hruban RH; Redston MS; Yeo CJ; Kern SE
Cancer Res; 1994 Jul; 54(13):3568-73. PubMed ID: 8012983
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas.
Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
Hepatogastroenterology; 2001; 48(39):879-83. PubMed ID: 11462947
[TBL] [Abstract][Full Text] [Related]
20. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas.
Ueda S; Fukamachi K; Matsuoka Y; Takasuka N; Takeshita F; Naito A; Iigo M; Alexander DB; Moore MA; Saito I; Ochiya T; Tsuda H
Carcinogenesis; 2006 Dec; 27(12):2497-510. PubMed ID: 16774944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
